RESULTS
Among the 72,026 women who initiated oral BP between 2004-2012 (mean age 70.8 AE 10.7 years; 65% non-Hispanic white, 17% Asian, 18% all others), 50,751 (70%) were 65 and older and 22,299 (31%) received a fracture diagnosis within the prior 5 years, including 17,294 with a fracture diagnosis in the past year. Those without prior fracture were more likely to be under age 65 (34% vs 19%, P < .001) and of Asian race (21% vs 9%, P < .001), compared to women with prior fracture.
Yearly (Figure 1A) , the proportions of younger women progressively declined from 31% to 17% while the proportions of older women increased from 69% to 83% (P < .001). These age-related trends were similarly observed among those with ( Figure 1B ) and without ( Figure 1C ) prior fracture. Among women who initiated BP and also did not have a prior fracture, the percentage under age 65 declined from 38% in 2008 to 19% in 2012 (P < .001). 
DISCUSSION
Between 2004-2012, oral BP initiation within our healthcare system shifted towards older women and those with prior fracture. These trends, apparent beginning in 2008, are consistent with increasing focus on primary and secondary fracture prevention of patients at elevated fracture risk. 6 In 2008, the World Health Organization introduced FRAX â , which integrates age, race/ethnicity, clinical risk factors, and bone mineral density (BMD) to estimate 10 -year fracture risk. 4, 7 Updated guidelines from the National Osteoporosis Foundation that same year emphasized treatment for postmenopausal women with hip or spine fracture, osteoporosis by BMD criteria, and osteopenia with high estimated fracture risk; 4, 8 this was in contrast to prior guidelines that included treatment of all postmenopausal women with T-score À2.0 or below (or À1.5 with risk factors), regardless of age. National quality metrics also emphasized osteoporosis testing and/ or treatment of women age 67 and older after a fracture, 9, 10 and osteoporosis testing for all women age 65 and older. 9, 10 In response to these national measures, regional outreach programs were developed within our health plan, beginning in 2008, focusing primarily on secondary fracture prevention and BMD screening in older women.
In summary, within Kaiser Permanente Northern California, we observed a substantial shift in BP treatment initiation that reflected changing practice in response to national guidelines and quality metrics. This included emphasizing treatment for older women and those experiencing fracture, with a 50% reduction in treatment of younger women without fracture. Implementation of our focused outreach programs likely prevented the reduction in BP prescriptions observed nationally.
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AN AUTOMATED APPROACH TO IDENTIFYING PATIENTS WITH DEMENTIA USING ELECTRONIC MEDICAL RECORDS
To the Editor: With the increased interest in clinical detection and management of Alzheimer's disease and related dementias, health systems and researchers have needed to quickly identify persons with these disorders to enroll them in care programs, recruit them into trials, and study the natural history and outcomes of dementia. This identification is generally done prospectively using a two-step process of screening followed by diagnostic assessment. However, this process is slow and expensive. To efficiently identify persons with dementia who could serve as a comparison group for a dementia management program, 1 we created and validated an automated electronic health record dementia identification method.
METHODS
We initially focused on 3 data sources contained in the UCLA electronic health record (an Epic-based record) that would indicate the presence of dementia. These included: 2) documentation that the patient was taking medications whose primary indication is to treat dementia (cholinesterase inhibitors and memantine); and (3) natural language processing (NLP) of history and physical notes, consult notes, discharge summary notes, and progress notes for evidence of patient dementia. In the NLP logic, dementia was operationalized as the presence of the terms "dementia" or "neurodegenerative" without the presence of any of the following markers in the same statement: (1) negating words, such as "not", "negative", or "ruled out"; (2) words that referred to the patient's family history or a family member's dementia status, such as "family history", "wife", or "husband"; or (3) words that indicated uncertainty, such as "suspected", "possible", or "risk".
We first examined the positive predictive value (PPV), true positives divided by all positives, of various combinations of these elements (all 3 elements and 3 different combinations of 2 elements) in diagnosing dementia compared to the gold standard of identification of documentation of dementia diagnosis by a physician during a medical record review. Physicians reviewed 60 medical records (15 patients meeting each combination, 5 in each of 3 age groups-40-64, 65-84, 85 and older). Early on, we noted a high number of false positives in the younger age group (45-64 years) and restricted the identification method in younger patients to only those who had dementia ICD-9 documented on at least two encounters. Based on initial analyses, the medications element was dropped and we reviewed an additional 64 cases that were identified only by NLP+ICD9 elements. PPV for patients of all ages and for those ≥65 years were weighted by their age representation in the entire dementia sample identified by the algorithm. Lastly, we estimated the sensitivity of the final and 3 element algorithms by applying these to the 989 patients who were enrolled in the UCLA Alzheimer's and Dementia Care (ADC) program with verified dementia. To produce a better estimate of how the algorithm would perform under typical circumstances, the dementia status of the patient was evaluated as of 3 weeks prior to ADC program start; this prevented the algorithm from taking advantage of the large volume of dementia-related documentation generated when a patient joined the program.
RESULTS
Findings are presented in Table 1 . The 3-element model had a PPV of 87% but the 2-element models that included medications were considerably lower (27% and 47%). Based on this examination, we dropped medications from the method. When analyzed by age group, the approach was much less accurate among those 40-64 years; when this younger group was excluded, the PPV was high (93%). When the final algorithm was tested on patients of all ages with verified dementia, the sensitivity was 63% but only 35% if all 3 elements were required. 
